<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of causes of anemia in children due to decreased red blood cell production</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of causes of anemia in children due to decreased red blood cell production</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of causes of anemia in children due to decreased red blood cell production</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anupama Narla, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Claudio Sandoval, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anemias caused by decreased red blood cell (RBC) production are characterized by an inappropriately low reticulocyte count. They are often grouped under the broader category of bone marrow failure, although their mechanisms and/or presentations may be markedly different and other diagnoses need to be explored (<a class="graphic graphic_table graphicRef80295" href="/z/d/graphic/80295.html" rel="external">table 1</a>).</p><p>This topic review outlines the main causes of anemia due to decreased RBC production, focusing on congenital and acquired pure red cell aplasia (PRCA) and congenital dyserythropoiesis.</p><p>The general approach to evaluating a child with anemia and detailed discussion of specific causes of anemia with decreased RBC production are provided separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5927.html" rel="external">"Approach to the child with anemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6491.html" rel="external">"Childhood lead poisoning: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5923.html" rel="external">"Treatment of acquired aplastic anemia in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131283.html" rel="external">"Diamond-Blackfan anemia"</a>.)</p><p></p><p class="headingAnchor" id="H1413430135"><span class="h1">PURE RED CELL APLASIA</span><span class="headingEndMark"> — </span>Disorders resulting in isolated anemia with reticulocytopenia are grouped together in the category of pure red cell aplasia (PRCA). PRCAs are generally characterized by:</p><p class="bulletIndent1"><span class="glyph">●</span>Normochromic and normocytic or macrocytic anemia (normal hematologic parameters for children are summarized in the table (<a class="graphic graphic_table graphicRef101544" href="/z/d/graphic/101544.html" rel="external">table 2</a>))</p><p class="bulletIndent1"><span class="glyph">●</span>Inappropriately low reticulocyte count </p><p class="bulletIndent1"><span class="glyph">●</span>Other cell lines are usually not affected</p><p class="bulletIndent1"><span class="glyph">●</span>Overall bone marrow cellularity is normal, with either decreased or absent erythroid precursors</p><p></p><p>PRCA in children may be congenital (eg, Diamond-Blackfan anemia [DBA]) or acquired (eg, transient erythroblastopenia of childhood [TEC] or an erythroblastopenic crisis in a patient with underlying chronic hemolytic anemia).</p><p>The characteristic finding of PRCA is isolated anemia with reticulocytopenia. When interpreting the reticulocyte count, attention must be paid to the particular reticulocyte parameter reported (percentage versus absolute count). It is often helpful to estimate the corrected reticulocyte count (ie, the reticulocyte count corrected for the degree of anemia). This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5927.html" rel="external">"Approach to the child with anemia", section on 'Reticulocyte count'</a>.)</p><p class="headingAnchor" id="H2"><span class="h2">Congenital causes</span></p><p class="headingAnchor" id="H3"><span class="h3">Diamond-Blackfan anemia</span><span class="headingEndMark"> — </span>DBA is a congenital erythroid aplasia that usually presents in infancy. It is characterized by the following features (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive normochromic, usually macrocytic anemia in infancy or early childhood</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Normal cellularity of the bone marrow with markedly decreased or absent erythroid precursors</p><p class="bulletIndent1"><span class="glyph">●</span>White blood cell count is generally normal; platelet counts are generally normal but can be increased or decreased</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital malformations (50 percent of patients) (<a class="graphic graphic_table graphicRef67544" href="/z/d/graphic/67544.html" rel="external">table 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of malignancies</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of endocrine dysfunction</p><p></p><p>DBA is caused by genetic mutations affecting ribosome synthesis. This results in stabilization and activation of protein p53 of tumor suppressor pathway, which is thought to be the one of the causes of the clinical manifestations, including impaired erythropoiesis.</p><p>DBA is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/131283.html" rel="external">"Diamond-Blackfan anemia"</a>.)</p><p class="headingAnchor" id="H2075700804"><span class="h3">Other congenital causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aase syndrome</strong> – The name "Aase syndrome" has been used to describe patients with congenital anemia, triphalangeal thumbs, cleft lip-palate, and cardiac defects [<a href="#rid1">1,2</a>]. However, Aase syndrome is probably a variant of DBA rather than a distinct clinical entity [<a href="#rid3">3-5</a>]. (See  <a class="medical medical_review" href="/z/d/html/131283.html" rel="external">"Diamond-Blackfan anemia", section on 'Physical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pearson marrow pancreas syndrome</strong> – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F557000&amp;token=G%2BkOOgscg7PQzd0gXq5S9%2FMZN1T9G0wySjw1trA63In5WIOjFaV9cOo9H%2BQZvRcz&amp;TOPIC_ID=5931" target="_blank">Pearson marrow pancreas syndrome</a> is a relatively rare condition that overlaps with the features of DBA. This condition can be diagnosed via mitochondrial deoxyribonucleic acid (DNA) deletion testing. Clinical features are not always sufficient to distinguish these disorders. The anemia associated with Pearson marrow pancreas syndrome is generally categorized as sideroblastic anemia rather than PRCA. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Pearson syndrome (large deletion of mitochondrial DNA)'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Acquired causes</span><span class="headingEndMark"> — </span>TEC and infection-associated RBC aplasia (eg, due to parvovirus B19) are relatively common causes of PRCA in children, whereas the other acquired conditions are rarely seen in children (<a class="graphic graphic_table graphicRef122462" href="/z/d/graphic/122462.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H11"><span class="h3">Transient erythroblastopenia of childhood</span><span class="headingEndMark"> — </span>TEC is a transient or temporary red cell aplasia, distinguishing it from the chronic inherited condition, DBA [<a href="#rid6">6-8</a>]. It is a self-limited anemia that typically occurs in previously healthy young children between the ages of one and four years. It is the most common cause of PRCA in children, and it is likely that many cases are subclinical. TEC should be suspected in an otherwise healthy child with anemia and reticulocytopenia. An extensive evaluation usually is not necessary, provided that the mean corpuscular volume (MCV) is normal and the blood smear does not suggest a primary RBC disorder or malignancy.</p><p class="headingAnchor" id="H12"><span class="h4">Etiology</span><span class="headingEndMark"> — </span>The etiology of TEC is unknown, but possible causes include viral illness, serum inhibitors against erythroid progenitor cells, and cell-mediated suppression of erythropoiesis [<a href="#rid9">9-12</a>]. A genetic predisposition has been postulated but not established.</p><p>In approximately one-half of the cases, children have a history of a viral illness in the preceding two to three months [<a href="#rid8">8,13</a>]. Echovirus 11, human herpesvirus type 6, and parvovirus have all been reported to be associated with the development of TEC [<a href="#rid9">9,10,14</a>]. In particular, an association with parvovirus serotype 19 has been suggested but not generally supported by virologic investigations. For example, in one case of TEC, parvovirus B19 genome was detected in blood and bone marrow at diagnosis and no longer detected when TEC resolved clinically [<a href="#rid15">15</a>]. However, in a series of 16 patients ages 3 to 23 months with TEC, amplification for parvovirus B19 from bone marrow was negative, suggesting parvovirus may not be the cause of TEC in young patients [<a href="#rid16">16</a>]. Seasonal clustering has been noted in small groups of patients. However, when large groups of patients are reviewed, no overall seasonal predominance is appreciated [<a href="#rid17">17,18</a>], speaking against a specific viral etiology.</p><p>Reports describing TEC occurring simultaneously or separately in siblings support the possibility of a genetic predisposition [<a href="#rid19">19-21</a>].</p><p class="headingAnchor" id="H13"><span class="h4">Clinical findings</span><span class="headingEndMark"> — </span>TEC usually occurs in children between the ages of one and four years [<a href="#rid7">7,8</a>]. It is uncommon in infants &lt;6 months old and in children &gt;6 years old; however, cases in young infants have been reported [<a href="#rid22">22,23</a>]. Males may be affected more often than females, and TEC has been seen in all ethnic groups [<a href="#rid8">8</a>]. TEC typically presents in children who are otherwise healthy.</p><p class="headingAnchor" id="H14"><span class="h4">Hematologic findings</span><span class="headingEndMark"> — </span>Patients generally present with mild to moderate anemia (hemoglobin [Hgb] in the range of 6 to 8 g/dL) with reticulocytopenia [<a href="#rid18">18</a>]. Mild neutropenia has been noted in ≥50 percent of patients with TEC in several series, and platelet counts may be normal or elevated [<a href="#rid18">18,24,25</a>]. In contrast with patients with DBA, patients with TEC do not have an elevated RBC MCV at diagnosis, nor do they have an increased percentage of fetal Hgb (Hgb F) or i antigen, and erythrocyte adenosine deaminase (eADA) activity is almost always normal (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 3</a>) [<a href="#rid26">26</a>]. Prior blood counts, if available, generally show normal Hgb concentrations [<a href="#rid22">22</a>]. Patients with TEC may have a slightly elevated MCV at the time of recovery because of the increased number of reticulocytes.</p><p>TEC may be distinguished from DBA based on the above clinical and laboratory data (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 3</a>). These data may obviate the need for a bone marrow examination in some patients [<a href="#rid18">18</a>]. Distinguishing between DBA and TEC patients who present with hypoplastic anemia in the first year of life may be particularly challenging. In this setting, serial measurements of Hgb, MCV, and reticulocyte count can be helpful [<a href="#rid22">22</a>]. The reticulocyte count typically starts to increase within one to two weeks in patients with TEC and Hgb and MCV typically normalize within one to two months. By contrast, patients with DBA are expected to have persistently low reticulocyte count, low Hgb, and elevated MCVs for age.</p><p class="headingAnchor" id="H15"><span class="h4">Treatment</span><span class="headingEndMark"> — </span>Management of TEC is purely supportive. The typical clinical course of TEC consists of anemia of one to two months' duration, followed by complete recovery. At the time of presentation, 5 to 10 percent of patients are already in the recovery phase, with 80 percent recovering within one month [<a href="#rid8">8,17</a>] and the remainder within two months [<a href="#rid13">13</a>]. Reports of the timing of neutrophil recovery are variable, with some studies finding that the absolute neutrophil count returns to normal prior to the appearance of reticulocytes, while others found that white blood cell recovery has no relation to the recovery of the anemia [<a href="#rid18">18,25</a>].</p><p>In our experience, children with TEC tolerate the anemia remarkably well and RBC transfusions are rarely required (eg, only if the patient has cardiorespiratory symptoms or fatigue that interferes with their quality of life). We do not use glucocorticoids to treat TEC. Though there are reports of using steroid therapy in this setting, there is no convincing evidence that it hastens recovery [<a href="#rid17">17</a>]. Given the benign nature of TEC, we believe the known adverse effects of systemic steroids outweigh any potential benefit.</p><p class="headingAnchor" id="H16"><span class="h3">Infections</span><span class="headingEndMark"> — </span>Parvovirus B19 is the infectious agent most commonly associated with acquired red cell aplasia; however, other infectious agents have been described (including hepatitis A, B, and C; Epstein-Barr virus; and human immunodeficiency virus [HIV]) [<a href="#rid27">27-32</a>]. Whether parvovirus is responsible for some cases of TEC is not clear, as discussed above. (See <a class="local">'Transient erythroblastopenia of childhood'</a> above.)</p><p>Human parvovirus B19 is a common infection that results in erythema infectiosum (fifth disease) in childhood, which is characterized by a classic erythematous malar rash (the so-called slapped cheek rash (<a class="graphic graphic_picture graphicRef89522 graphicRef71737" href="/z/d/graphic/89522.html" rel="external">picture 1A-B</a>)), often followed several days later by a reticulated or lacelike rash on the trunk and extremities (<a class="graphic graphic_picture graphicRef122702" href="/z/d/graphic/122702.html" rel="external">picture 2</a>). (See  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a>.)</p><p>Parvovirus infection can result in a temporary cessation of RBC production. The impact of parvovirus infection varies depending on whether the patient has an underlying condition:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with underlying chronic hemolytic anemia – In patients with chronic hemolytic anemias (eg, sickle cell anemia, thalassemia, pyruvate kinase deficiency, autoimmune hemolytic anemia, spherocytosis, pyropoikilocytosis, and elliptocytosis), the temporary cessation of RBC production may result in severe anemia or "aplastic (erythroblastopenic) crisis." (See  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Aplastic crisis'</a> and  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Transient aplastic crisis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised patients – Immunocompromised patients (eg, transplant recipients, patients with HIV, those receiving immunosuppressive therapy) are at risk for the development of chronic anemia with parvovirus infections because of their impaired ability to clear the viral infection. (See  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Chronic infection in immunosuppressed hosts'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompetent host – In patients without underlying immunodeficiency or chronic anemia, the temporary cessation of RBC production usually does not have any clinical consequences (<a class="graphic graphic_figure graphicRef75004" href="/z/d/graphic/75004.html" rel="external">figure 1</a>). Rarely, a healthy patient will experience significant RBC aplasia and develop clinically significant anemia due to parvovirus infection. In such patients, it is prudent to perform testing to exclude a previously unsuspected underlying chronic hemolytic anemia or immune disorder. Occasionally, patients with well-compensated and hereditary hemolytic anemias are diagnosed following presentation with parvovirus-induced RBC aplasia [<a href="#rid33">33,34</a>].</p><p></p><p>The microbiology, epidemiology, clinical manifestations, diagnosis, and treatment of parvovirus B19 infection are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8274.html" rel="external">"Virology, epidemiology, and pathogenesis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">"Treatment and prevention of parvovirus B19 infection"</a>.)</p><p class="headingAnchor" id="H409046399"><span class="h3">Other acquired causes</span><span class="headingEndMark"> — </span>Rarely, PRCA can occur in children due to other acquired causes, including drugs, thymoma, malignancies, ABO-incompatible allogenic transplant, and autoimmune disorders (eg, systemic lupus erythematosus, rheumatoid arthritis; however, autoimmune disorders more commonly cause autoimmune hemolytic anemia rather than PRCA) (<a class="graphic graphic_table graphicRef122462" href="/z/d/graphic/122462.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">"Clinical presentation and management of thymoma and thymic carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Hematologic'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">BONE MARROW FAILURE</span><span class="headingEndMark"> — </span>Bone marrow failure syndromes other than DBA include acquired aplastic anemia, Fanconi anemia, and Shwachman-Diamond syndrome. These disorders affect granulocytes and/or platelets in addition to RBCs but may present with hypoplastic anemia. Malignancy and myelofibrosis may also result in bone marrow replacement, causing anemia with a poor reticulocyte response. Metabolic causes of myelofibrosis include hypoparathyroidism, chronic renal failure, and vitamin deficiency [<a href="#rid35">35</a>].</p><p>Bone marrow failure syndromes are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired aplastic anemia (see  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5923.html" rel="external">"Treatment of acquired aplastic anemia in children and adolescents"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Fanconi anemia (see  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a> and  <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">"Management and prognosis of Fanconi anemia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Shwachman-Diamond syndrome (see  <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Dyskeratosis congenita (see  <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Myelofibrosis (see  <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a> and  <a class="medical medical_review" href="/z/d/html/4526.html" rel="external">"Pathogenetic mechanisms in primary myelofibrosis"</a> and  <a class="medical medical_review" href="/z/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">IMPAIRED ERYTHROPOIETIN PRODUCTION</span></p><p class="headingAnchor" id="H3768556199"><span class="h2">Physiology of erythropoietin</span><span class="headingEndMark"> — </span>Erythropoietin (EPO) is the growth factor responsible for the regulation of RBC production. It is produced initially in the fetal and neonatal liver and, subsequently, primarily in the kidneys. EPO is part of a complex regulatory system, adjusting RBC production based upon tissue oxygen demand [<a href="#rid36">36</a>]. Hypoxic conditions (ie, anemia), as well as a fall in the arterial oxygen pressure (eg, from cardiopulmonary disease or exposure to high altitude), stimulate EPO production and thus RBC production.</p><p>Metabolic factors may influence EPO production. For example, hypothyroidism, starvation, and hypophysectomy result in reduced EPO levels, and stimulation of thyroid hormone results in increased EPO levels [<a href="#rid37">37,38</a>]. Abnormally low EPO production, or failure of EPO levels to rise in the face of hypoxia, may result in anemia with a poor reticulocyte response. (See  <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">"Regulation of erythropoiesis", section on 'Erythropoietin'</a>.)</p><p class="headingAnchor" id="H938716489"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>Children with chronic kidney disease may have normocytic anemia that is likely multifactorial but is largely caused by low EPO levels. Anemia in chronic kidney disease is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Anemia of chronic disease</span><span class="headingEndMark"> — </span>Anemia of chronic disease is multifactorial and is usually associated with the presence of infection, inflammation, or malignancy. Anemia of chronic disease is usually a mild anemia with either normocytic or microcytic cells and reticulocytopenia. The presence of normal to elevated ferritin concentrations distinguishes anemia of chronic disease from iron deficiency anemia, in which ferritin concentration is low.</p><p>Anemia of chronic disease is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">ERYTHROID MATURATION DISORDERS AND INEFFECTIVE ERYTHROPOIESIS</span><span class="headingEndMark"> — </span>Disorders of erythroid maturation or ineffective erythropoiesis may also result in anemia with reticulocytopenia.</p><p class="headingAnchor" id="H3420589189"><span class="h2">Common acquired causes</span><span class="headingEndMark"> — </span>Common acquired causes of anemia that fall into this category are reviewed in detail separately. </p><p class="headingAnchor" id="H1329022601"><span class="h3">Iron deficiency anemia</span><span class="headingEndMark"> — </span>Iron deficiency in childhood is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">"Iron requirements and iron deficiency in adolescents"</a>.)</p><p class="headingAnchor" id="H3986410266"><span class="h3">Sideroblastic anemias</span><span class="headingEndMark"> — </span>Sideroblastic anemias are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias"</a> and  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management"</a>.)</p><p class="headingAnchor" id="H932019065"><span class="h3">Lead poisoning</span><span class="headingEndMark"> — </span>Lead poisoning is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6491.html" rel="external">"Childhood lead poisoning: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H641938051"><span class="h3">Megaloblastic anemias</span><span class="headingEndMark"> — </span>Megaloblastic anemia (eg, due to vitamin B12 or folate deficiency) is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Congenital dyserythropoietic anemia</span><span class="headingEndMark"> — </span>The congenital dyserythropoietic anemias (CDAs) are a group of rare disorders characterized by anemia due to ineffective erythropoiesis and multinuclear erythroblasts (<a class="graphic graphic_figure graphicRef51418" href="/z/d/graphic/51418.html" rel="external">figure 2</a>) [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H2698496333"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>The clinical features, laboratory and bone marrow examination findings, and genetics of the different CDA types are summarized in the table (<a class="graphic graphic_figure graphicRef51418" href="/z/d/graphic/51418.html" rel="external">figure 2</a>). Key features include [<a href="#rid39">39-42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia with reticulocytopenia – The anemia in CDA can range from mild to severe. It is usually macrocytic or normocytic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multinuclear erythroblasts – On bone marrow examination, the characteristic finding in all types of CDA is the presence of multinuclear erythroblasts. The presence of binucleated normoblasts on the peripheral blood smear is highly suggestive of CDA, particularly [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemolysis – In CDA types II, III, and IV, there is typically evidence of hemolysis, which may include abnormalities on biochemical tests (eg, elevated indirect bilirubin, elevated LDH, etc) and/or clinical findings (eg, jaundice). Patients with type II and type IV CDA may also have splenomegaly, whereas splenomegaly is not a characteristic finding in type III CDA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron overload – Iron overload, caused by increased absorption of intestinal iron as well as chronic transfusions, is a problem for patients with all types of CDA [<a href="#rid44">44,45</a>]. It is, at least in part, related to the presence of severe degrees of ineffective erythropoiesis, along with inappropriate suppression of hepcidin [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Ineffective erythropoiesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonhematologic findings – Patients with some forms of CDA (particularly type I) may have nonhematologic findings, most commonly skeletal abnormalities involving the distal extremities, chest wall deformities, and short stature. </p><p></p><p class="headingAnchor" id="H3051407612"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of CDA is confirmed with genetic testing. At most centers, the preferred approach to genetic testing is next-generation sequencing (NGS) using a targeted panel. A list of laboratories performing testing for CDAs and other hereditary anemias is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=5931" target="_blank">Genetic Testing Registry website</a>. If NGS is not available, single gene testing may be appropriate in patients with convincing clinical and laboratory findings.</p><p class="headingAnchor" id="H24"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Therapy depends upon the type of CDA and severity of anemia [<a href="#rid39">39,40,43,45,47,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Transfusions may be required for patients with severe anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interferon alfa may be effective in patients with CDA type I.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Splenectomy may be effective for patients with CDA type II, though it results in only modest improvement in the anemia and thus is generally reserved for patients with severe anemia and/or symptomatic splenomegaly. Splenectomy is associated with increased risk of thromboembolic events and life-long infection risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron chelation therapy may be required for treatment of iron overload, particularly in transfusion-dependent patients [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of note, iron supplementation should be <strong>avoided</strong> since patients with CDA have increased absorption of intestinal iron and tend to have problems with iron overload even in the absence of transfusion [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematopoietic cell transplantation (HCT) is a potentially curative therapy that has been described in patients with CDA [<a href="#rid49">49-52</a>].</p><p></p><p class="headingAnchor" id="H9672399"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong> – Anemias caused by decreased red blood cell (RBC) production can be categorized according to the mechanism as follows (<a class="graphic graphic_table graphicRef80295" href="/z/d/graphic/80295.html" rel="external">table 1</a>) (see <a class="local">'Introduction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pure red cell aplasia (PRCA), either congenital or acquired (<a class="graphic graphic_table graphicRef122462" href="/z/d/graphic/122462.html" rel="external">table 5</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow failure involving more than one cell line</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia caused by marrow replacement (malignancy, storage disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia caused by decreased erythropoietin (EPO) availability</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia related to ineffective erythropoiesis</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia caused by disordered erythroid maturation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pure red cell aplasia</strong> – PRCAs are disorders with decreased RBC production without involvement of other cell lines. They are characterized by reticulocytopenia and anemia, which is generally normochromic and normocytic or macrocytic. (See <a class="local">'Pure red cell aplasia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diamond-Blackfan anemia (DBA) is a congenital PRCA that usually presents in infancy. Approximately one-half of patients with DBA have associated malformations, most commonly craniofacial and upper limb anomalies (<a class="graphic graphic_table graphicRef67544" href="/z/d/graphic/67544.html" rel="external">table 4</a>). DBA is associated with a predisposition to cancer. Diagnosis and management of DBA are discussed separately. (See <a class="local">'Diamond-Blackfan anemia'</a> above and  <a class="medical medical_review" href="/z/d/html/131283.html" rel="external">"Diamond-Blackfan anemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transient erythroblastopenia of childhood (TEC) is a self-limited red cell aplasia due to a temporary cessation of erythrocyte production that typically occurs in previously healthy children between the ages of one and four years. The etiology is unclear. TEC is the most common cause of PRCA in children and should be suspected in an otherwise healthy child with anemia and reticulocytopenia. The clinical picture, laboratory findings, and course can help distinguish TEC from DBA (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 3</a>). (See <a class="local">'Transient erythroblastopenia of childhood'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infections can also cause acquired PRCA in children. The most common infectious cause of acquired red cell aplasia is parvovirus B19. Other infectious causes include hepatitis A, B, and C; Epstein-Barr virus; and HIV. (See <a class="local">'Infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noninfectious causes of acquired red cell aplasia include drugs, autoimmune disorders (eg, systemic lupus erythematosus, rheumatoid arthritis), thymoma, and malignancies (<a class="graphic graphic_table graphicRef122462" href="/z/d/graphic/122462.html" rel="external">table 5</a>). These are uncommon causes of PRCA in children. (See <a class="local">'Infections'</a> above and <a class="local">'Acquired causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow failure or infiltration</strong> – Bone marrow failure resulting in red cell aplasia can be caused by acquired aplastic anemia, Fanconi anemia, Shwachman-Diamond syndrome or other inherited bone marrow failure syndrome, infiltrating malignancies, or myelofibrosis. These disorders are discussed separately. (See <a class="local">'Bone marrow failure'</a> above and  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a> and  <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired EPO production</strong> – The two main causes in this category are chronic kidney disease and anemia of chronic disease, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a> and  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of erythroid maturation/ineffective erythropoiesis</strong> – A variety of disorders cause anemia because of ineffective erythropoiesis or disordered erythroid maturation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acquired causes – Common acquired causes of anemia that fall into this category are reviewed in detail separately. These include the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Iron deficiency (see  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">"Iron requirements and iron deficiency in adolescents"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Sideroblastic anemias (see  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Acquired sideroblastic anemias'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Lead poisoning (see  <a class="medical medical_review" href="/z/d/html/6491.html" rel="external">"Childhood lead poisoning: Clinical manifestations and diagnosis"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Megaloblastic anemias (see  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital dyserythropoietic anemias (CDA) – CDAs are a group of rare disorders characterized by anemia due to ineffective erythropoiesis and multinuclear erythroblasts (<a class="graphic graphic_figure graphicRef51418" href="/z/d/graphic/51418.html" rel="external">figure 2</a>). Treatment depends on the specific type and severity of anemia. (See <a class="local">'Congenital dyserythropoietic anemia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aase JM, Smith DW. Congenital anemia and triphalangeal thumbs: a new syndrome. J Pediatr 1969; 74:471.</a></li><li><a class="nounderline abstract_t">Muis N, Beemer FA, van Dijken P, Klep-de Pater JM. The Aase syndrome. Case report and review of the literature. Eur J Pediatr 1986; 145:153.</a></li><li><a class="nounderline abstract_t">Alter BP. Thumbs and anemia. Pediatrics 1978; 62:613.</a></li><li><a class="nounderline abstract_t">Hurst JA, Baraitser M, Wonke B. Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities. Am J Med Genet 1991; 40:482.</a></li><li class="breakAll">Clinton C, Gazda HT. Diamond-Blackfan anemia. GeneReviews (internet). Available at: http://www.ncbi.nlm.nih.gov/books/NBK7047/.</li><li><a class="nounderline abstract_t">Wranne L. Transient erythroblastopenia in infancy and childhood. Scand J Haematol 1970; 7:76.</a></li><li><a class="nounderline abstract_t">Lovric VA. Anaemia and temporary erythroblastopaenia in children. A syndrome. Australas Ann Med 1970; 19:34.</a></li><li><a class="nounderline abstract_t">Oski FA. Transient Erythroblastopenia. Pediatr Rev 1982; 4:25.</a></li><li><a class="nounderline abstract_t">Penchansky L, Jordan JA. Transient erythroblastopenia of childhood associated with human herpesvirus type 6, variant B. Am J Clin Pathol 1997; 108:127.</a></li><li><a class="nounderline abstract_t">Elian JC, Frappaz D, Pozzetto B, Freycon F. Transient erythroblastopenia of childhood presenting with echovirus 11 infection. Acta Paediatr 1993; 82:492.</a></li><li><a class="nounderline abstract_t">Dessypris EN, Krantz SB, Roloff JS, Lukens JN. Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children. Blood 1982; 59:114.</a></li><li><a class="nounderline abstract_t">Tamary H, Kaplinsky C, Shvartzmayer S, et al. Transient erythroblastopenia of childhood. Evidence for cell-mediated suppression of erythropoiesis. Am J Pediatr Hematol Oncol 1993; 15:386.</a></li><li><a class="nounderline abstract_t">Mupanomunda OK, Alter BP. Transient erythroblastopenia of childhood (TEC) presenting as leukoerythroblastic anemia. J Pediatr Hematol Oncol 1997; 19:165.</a></li><li><a class="nounderline abstract_t">Wodzinski MA, Lilleyman JS. Transient erythroblastopenia of childhood due to human parvovirus B19 infection. Br J Haematol 1989; 73:127.</a></li><li><a class="nounderline abstract_t">Prassouli A, Papadakis V, Tsakris A, et al. Classic transient erythroblastopenia of childhood with human parvovirus B19 genome detection in the blood and bone marrow. J Pediatr Hematol Oncol 2005; 27:333.</a></li><li><a class="nounderline abstract_t">Rogers BB, Rogers ZR, Timmons CF. Polymerase chain reaction amplification of archival material for parvovirus B19 in children with transient erythroblastopenia of childhood. Pediatr Pathol Lab Med 1996; 16:471.</a></li><li><a class="nounderline abstract_t">Gerrits GP, van Oostrom CG, de Vaan GA, Bakkeren JA. Transient erythroblastopenia of childhood. A review of 22 cases. Eur J Pediatr 1984; 142:266.</a></li><li><a class="nounderline abstract_t">Hays T, Lane PA Jr, Shafer F. Transient erythroblastopenia of childhood. A review of 26 cases and reassessment of indications for bone marrow aspiration. Am J Dis Child 1989; 143:605.</a></li><li><a class="nounderline abstract_t">Labotka RJ, Maurer HS, Honig GR. Transient erythroblastopenia of childhood. Review of 17 cases, including a pair of identical twins. Am J Dis Child 1981; 135:937.</a></li><li><a class="nounderline abstract_t">Shaw J, Meeder R. Transient erythroblastopenia of childhood in siblings: case report and review of the literature. J Pediatr Hematol Oncol 2007; 29:659.</a></li><li><a class="nounderline abstract_t">Skeppner G, Forestier E, Henter JI, Wranne L. Transient red cell aplasia in siblings: a common environmental or a common hereditary factor? Acta Paediatr 1998; 87:43.</a></li><li><a class="nounderline abstract_t">Ware RE, Kinney TR. Transient erythroblastopenia in the first year of life. Am J Hematol 1991; 37:156.</a></li><li><a class="nounderline abstract_t">Miller R, Berman B. Transient erythroblastopenia of childhood in infants &lt; 6 months of age. Am J Pediatr Hematol Oncol 1994; 16:246.</a></li><li><a class="nounderline abstract_t">Rogers ZR, Bergstrom SK, Amylon MD, et al. Reduced neutrophil counts in children with transient erythroblastopenia of childhood. J Pediatr 1989; 115:746.</a></li><li><a class="nounderline abstract_t">Cherrick I, Karayalcin G, Lanzkowsky P. Transient erythroblastopenia of childhood. Prospective study of fifty patients. Am J Pediatr Hematol Oncol 1994; 16:320.</a></li><li><a class="nounderline abstract_t">Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol 2008; 142:859.</a></li><li><a class="nounderline abstract_t">Ide T, Sata M, Nouno R, et al. Clinical evaluation of four cases of acute viral hepatitis complicated by pure red cell aplasia. Am J Gastroenterol 1994; 89:257.</a></li><li><a class="nounderline abstract_t">al-Awami Y, Sears DA, Carrum G, et al. Pure red cell aplasia associated with hepatitis C infection. Am J Med Sci 1997; 314:113.</a></li><li><a class="nounderline abstract_t">Davidovitz Y, Halpern Z, Wardi J, et al. Pure red cell aplasia responsive to interferon-alpha in a patient with hepatitis C virus infection. Acta Haematol 1998; 100:213.</a></li><li><a class="nounderline abstract_t">Parmentier L, Boucary D, Salmon D. Pure red cell aplasia in an HIV-infected patient. AIDS 1992; 6:234.</a></li><li><a class="nounderline abstract_t">Purtilo DT, Zelkowitz L, Harada S, et al. Delayed onset of infectious mononucleosis associated with acquired agammaglobulinemia and red cell aplasia. Ann Intern Med 1984; 101:180.</a></li><li><a class="nounderline abstract_t">Socinski MA, Ershler WB, Tosato G, Blaese RM. Pure red blood cell aplasia associated with chronic Epstein-Barr virus infection: evidence for T cell-mediated suppression of erythroid colony forming units. J Lab Clin Med 1984; 104:995.</a></li><li><a class="nounderline abstract_t">Lefrere JJ, Courouce AM, Girot R, et al. Six cases of hereditary spherocytosis revealed by human parvovirus infection. Br J Haematol 1986; 62:653.</a></li><li><a class="nounderline abstract_t">Skinnider LF, McSheffrey BJ, Sheridan D, Deneer H. Congenital spherocytic hemolytic anemia in a family presenting with transient red cell aplasia from parvovirus B19 infection. Am J Hematol 1998; 58:341.</a></li><li class="breakAll">Shimamura A, Guinan G. Acquired aplastic anemia. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.256.</li><li><a class="nounderline abstract_t">Van Damme-Lombaerts R, Herman J. Erythropoietin treatment in children with renal failure. Pediatr Nephrol 1999; 13:148.</a></li><li><a class="nounderline abstract_t">Nomiyama J, Shinohara K, Inoue H. Improvement of anemia by recombinant erythropoietin in a patient with postoperative hypopituitarism. Am J Hematol 1994; 47:249.</a></li><li><a class="nounderline abstract_t">Das KC, Mukherjee M, Sarkar TK, et al. Erythropoiesis and erythropoietin in hypo- and hyperthyroidism. J Clin Endocrinol Metab 1975; 40:211.</a></li><li><a class="nounderline abstract_t">Iolascon A, Andolfo I, Russo R. Congenital dyserythropoietic anemias. Blood 2020; 136:1274.</a></li><li><a class="nounderline abstract_t">Gambale A, Iolascon A, Andolfo I, Russo R. Diagnosis and management of congenital dyserythropoietic anemias. Expert Rev Hematol 2016; 9:283.</a></li><li><a class="nounderline abstract_t">Iolascon A, Delaunay J, Wickramasinghe SN, et al. Natural history of congenital dyserythropoietic anemia type II. Blood 2001; 98:1258.</a></li><li><a class="nounderline abstract_t">Deguise MO, Blain S, Simpson E, et al. Congenital dyserythropoietic anemia type IV in the genetic era: A rare neonatal case report of rapid identification with a review of the literature. Pediatr Blood Cancer 2023; 70:e30245.</a></li><li><a class="nounderline abstract_t">Heimpel H, Anselstetter V, Chrobak L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. Blood 2003; 102:4576.</a></li><li><a class="nounderline abstract_t">Marks PW, Mitus AJ. Congenital dyserythropoietic anemias. Am J Hematol 1996; 51:55.</a></li><li><a class="nounderline abstract_t">Lavabre-Bertrand T, Blanc P, Navarro R, et al. alpha-Interferon therapy for congenital dyserythropoiesis type I. Br J Haematol 1995; 89:929.</a></li><li><a class="nounderline abstract_t">Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008; 112:5241.</a></li><li><a class="nounderline abstract_t">Heimpel H, Schwarz K, Ebnöther M, et al. Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood 2006; 107:334.</a></li><li><a class="nounderline abstract_t">Wickramasinghe SN, Wood WG. Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Haematol 2005; 131:431.</a></li><li><a class="nounderline abstract_t">Miano M, Eikema DJ, Aljurf M, et al. Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation. Haematologica 2019; 104:e335.</a></li><li><a class="nounderline abstract_t">Uygun V, Russo R, Karasu G, et al. Hematopoietic Stem Cell Transplantation in Congenital Dyserythropetic Anemia Type II: A Case Report and Review of the Literature. J Pediatr Hematol Oncol 2020; 42:e507.</a></li><li><a class="nounderline abstract_t">Iolascon A, Sabato V, de Mattia D, Locatelli F. Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II). Bone Marrow Transplant 2001; 27:213.</a></li><li><a class="nounderline abstract_t">Ayas M, al-Jefri A, Baothman A, et al. Transfusion-dependent congenital dyserythropoietic anemia type I successfully treated with allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:681.</a></li></ol></div><div id="topicVersionRevision">Topic 5931 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5764780" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Congenital anemia and triphalangeal thumbs: a new syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3732321" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Aase syndrome. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/714597" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thumbs and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746615" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746615" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5450690" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transient erythroblastopenia in infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5505519" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaemia and temporary erythroblastopaenia in children. A syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transient Erythroblastopenia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9260752" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transient erythroblastopenia of childhood associated with human herpesvirus type 6, variant B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8518530" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transient erythroblastopenia of childhood presenting with echovirus 11 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7053758" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214360" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Transient erythroblastopenia of childhood. Evidence for cell-mediated suppression of erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149751" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transient erythroblastopenia of childhood (TEC) presenting as leukoerythroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2553096" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transient erythroblastopenia of childhood due to human parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956889" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Classic transient erythroblastopenia of childhood with human parvovirus B19 genome detection in the blood and bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9025846" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polymerase chain reaction amplification of archival material for parvovirus B19 in children with transient erythroblastopenia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6593224" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transient erythroblastopenia of childhood. A review of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2718996" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transient erythroblastopenia of childhood. A review of 26 cases and reassessment of indications for bone marrow aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7293995" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transient erythroblastopenia of childhood. Review of 17 cases, including a pair of identical twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17805047" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Transient erythroblastopenia of childhood in siblings: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9510446" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transient red cell aplasia in siblings: a common environmental or a common hereditary factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1858769" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transient erythroblastopenia in the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8037344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Transient erythroblastopenia of childhood in infants&lt;6 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2809908" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Reduced neutrophil counts in children with transient erythroblastopenia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978049" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transient erythroblastopenia of childhood. Prospective study of fifty patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671700" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8304314" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical evaluation of four cases of acute viral hepatitis complicated by pure red cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9258213" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pure red cell aplasia associated with hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973647" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pure red cell aplasia responsive to interferon-alpha in a patient with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558724" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pure red cell aplasia in an HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6331239" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Delayed onset of infectious mononucleosis associated with acquired agammaglobulinemia and red cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6094693" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pure red blood cell aplasia associated with chronic Epstein-Barr virus infection: evidence for T cell-mediated suppression of erythroid colony forming units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3008804" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Six cases of hereditary spherocytosis revealed by human parvovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692404" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Congenital spherocytic hemolytic anemia in a family presenting with transient red cell aplasia from parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692404" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Congenital spherocytic hemolytic anemia in a family presenting with transient red cell aplasia from parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229005" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Erythropoietin treatment in children with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942799" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Improvement of anemia by recombinant erythropoietin in a patient with postoperative hypopituitarism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1117976" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Erythropoiesis and erythropoietin in hypo- and hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702750" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Congenital dyserythropoietic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26653117" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diagnosis and management of congenital dyserythropoietic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493480" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Natural history of congenital dyserythropoietic anemia type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36798023" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Congenital dyserythropoietic anemia type IV in the genetic era: A rare neonatal case report of rapid identification with a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12933587" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8571938" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Congenital dyserythropoietic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7772538" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : alpha-Interferon therapy for congenital dyserythropoiesis type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824595" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141353" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16281933" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Advances in the understanding of the congenital dyserythropoietic anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30679331" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31593005" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hematopoietic Stem Cell Transplantation in Congenital Dyserythropetic Anemia Type II: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11281393" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12180113" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transfusion-dependent congenital dyserythropoietic anemia type I successfully treated with allogeneic stem cell transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
